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Tumor infiltration by T cells is paramount for effective anti-cancer immune responses. We
hypothesized that the T cell receptor (TCR) repertoire of tumor infiltrating T lymphocytes
could therefore be indicative of the functional state of these cells and determine disease
course at different stages in cancer progression. Here we show that the diversity of the TCR
of tumor infiltrating T cell at baseline is prognostic in various cancers, whereas the TCR
clonality of T cell infiltrating metastatic melanoma pre-treatment is predictive for activity and
efficacy of PD1 blockade immunotherapy.
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Immunotherapy with programmed death 1 (PD1) checkpointblockade (CPB) is increasingly utilized to treat solid tumors inthe metastatic setting, where the response rate is 20–55%1, and
also as an adjuvant or neoadjuvant approach for locally advanced
disease. Unfortunately, the identification of the patients who will
benefit from treatment remains an unmet need, so to refine
patient care predictive biomarkers are required to identify
metastatic patients with better chances of responding to CPB.
Moreover, in the adjuvant setting, tools are needed to select
patients at lower risk of disease recurrence who have been cured
by surgery so that they can be spared the risk of CPB-associated
toxicity. The first biomarker strategies to emerge focused on the
quantification of the tumor mutational burden and the expression
of PD1 ligand (PD-L1) in the tumor microenvironment, but
additional tools are needed to improve accuracy and the dis-
tinction between prognostic and predictive biomarkers2,3.
The highly variable complementarity determining region 3
(CDR3) of the beta chain of the T cell receptor (TCR) is unique to
individual T cell clones and can therefore be used to monitor the
dynamics of T cell repertoire responses to CPB4. We recently
reported that immune checkpoint inhibition with PD1 CBP can
increase the clonality or the diversity of the TCR in peripheral
T cells after 3 weeks of treatment, and importantly this bifurcated
reaction only occurs in patients who respond to treatment5. This
approach therefore allows patient responses to be monitored
using minimally invasive liquid biopsies early during treatment.
Here we examine whether the TCR repertoire metrics in tumor-
infiltrating T lymphocytes (TIL/Tc) can also identify which
patients will benefit from CPB prior to commencement of therapy.
Results
Pre-treatment TIL/Tc clonality is predictive for CPB benefit.
To determine how the TCR repertoire of TIL/Tc influenced PD1
CPB outcome, we analyzed pre-treatment biopsies from 16
metastatic melanoma patients who received anti-PD1 agents in
Manchester, Padova, and Meldola (Table 1). There were no dif-
ferences in total TIL/Tc numbers, the number of TIL/Tc clones,
or the diversity and clonality of the TCR when comparing lymph-
node tumors and tumors from extranodal sites (Supplementary
Fig. 1a–d), suggesting that the lymph-node microenvironment
did not affect tumor infiltration by T cells. We also did not find
significant correlation between patient overall survival (OS) and
baseline peripheral serum lactic dehydrogenase levels, total
number of TIL/Tc, number of TIL/Tc clones, TCR diversity, the
number of non-synonymous single-nucleotide variants (SNVs),
or PD-L1 staining (Supplementary Table 1). However, we did
find better OS and reduced death hazard (Cox regression P=
0.0401, hazard ratio= 4.8 × 10−14, C-index= 0.88) correlated to
high TCR clonality in these pre-treatment tumor samples
(Fig. 1A, B). We validated our findings using published data from
106 metastatic melanoma patients biopsied prior to treatment
with PD1 or sequential PD1/CTLA4 blockade6,7. Here again,
better OS correlated with higher TIL/Tc TCR clonality (P=
0.0225, external validation C-index= 0.582, 95% confidence
interval= 0.501–0.664; Fig. 1C, D).
To ensure that OS was not confounded by subsequent
treatments, we also tested the correlation between TIL/Tc TCR
clonality and PD1 CPB response. In two independent metastatic
melanoma patient cohorts8,9, we found that pre-treatment TIL/Tc
TCR clonality was directly associated with the likelihood of
response for metastatic palliative and neoadjuvant PD1 CPB10
(Fig. 1E–H, area under the curve [AUC] of the receiver operating
curve [ROC]= 0.89 and 0.81and Fig. 1I, J, AUC of the ROC=
0.74, respectively), and although the numbers were too small to
draw conclusions, only patients with TIL/Tc TCR clonality above
the median have recurred at the time of analysis (Supplementary
Fig. 2a). Intriguingly, the analysis of TIL/Tc TCR clonality in the
on-treatment biopsy did not increase the performance of
the prediction for response (Supplementary Fig. 2b, c, AUC of
ROC= 0.74).
Notably, we observed consistency of our findings across the
two platforms (TCR reconstruction from RNA sequencing (RNA-
Seq) and targeted TCR sequencing) used to reconstruct the TCR
in these melanoma cohorts and also with no significant difference
in the overall TIL/Tc clonality, although TCR reconstruction
from the RNA-Seq data yielded overall fewer unique TCR
clonotypes than from the targeted TCR sequencing (Supplemen-
tary Fig. 3a, b). The cumulative CDR3 length was also comparable
in the samples analyzed with the two platforms (Supplementary
Fig. 3c), and we did not observe significant skewing of V gene
representation (Supplementary Fig. 4a, b), nor striking differences
in the similarity scores across samples, since these were largely
unrelated in the two series (Supplementary Fig. 5a, b). Thus, high
TCR clonality in the pre-treatment TIL/Tc population was
predictive for PD1 CPB activity and efficacy across multiple series
and using two methods to identify the TCR sequences.
TIL/Tc diversity is prognostic for OS of melanoma patients in
the absence of anti-PD1 inhibitors. To test whether high TIL/Tc
TCR clonality also correlated to prognosis in melanoma patients
who did not receive PD1 CPB, we analyzed the TIL/Tc TCR
repertoire in The Cancer Genome Atlas (TCGA) melanoma
cohort11, because the data-lock for these samples predated
approval of anti-PD1 inhibitors. As expected, in multivariate
analysis, age, clinical stage, and prevalence of single base sub-
stitution signature 7 (SBS7v2)12,13 were prognostic for OS (P <
0.001; Fig. 2A and Supplementary Table 2). Notably, whereas
TIL/Tc TCR clonality was not prognostic for survival in this
cohort (Supplementary Table 2), high TIL/Tc TCR diversity was
associated with better OS (Fig. 2B). Thus, high TCR diversity in
pre-treatment TIL/Tc was prognostic for OS in melanoma
patients who did not receive anti-PD1 treatments, and the
addition of TCR diversity to the standard clinical covariates sig-
nificantly increased the prognostic C-index (from 0.646 to 0.693,
analysis of variance P < 0.001). To quantify cumulative melanoma
risk based on these findings, we developed a nomogram to assist
clinical decisions (Fig. 2C) and provide an example of the use of
this tool (Supplementary Fig. 6).
TIL/Tc diversity is prognostic for OS across several cancer
histotypes. Since PD1 CPB is now standard of care for melanoma
Table 1 Training cohort clinical characteristics.
N (%) Median (range)












Lactic dehydrogenase (U/L) 287 (51–822)
The table shows the number of patients with the given characteristic with the percentage in
parentheses or the median value for the variable with the range in parentheses.
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in the adjuvant and metastatic settings, prospective analysis of
anti-PD1 naive melanoma patients who will not receive CPB in
their clinical history is no longer feasible, so we examined TIL/Tc
TCR diversity and clonality in other TCGA cancer cohorts. This
also allowed us to assess whether the prognostic value of pre-
treatment TIL/Tc is unique to melanoma or is shared by other
cancers. We focused on the cancers with an average TIL/Tc count
in the highest quartile (>317.5), which includes breast cancer
(BRCA), melanoma (SKCM), squamous lung carcinoma (LUSC),
lung adenoma (LUAD), thymoma (THYM), clear cell renal
cancer (KIRC), and testicular cancer (TGCT) (Fig. 3A and Sup-
plementary Tables 3–7). As in previous studies14, we restricted
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our LUSC analysis to patients with low cigarette use, and due to
insufficient OS events15, we used progression-free interval as the
TGCT endpoint. Also, due to the small number of events for
patients with TCR data, we could not perform regression analysis
for THYM15. Despite these restrictions, we found that high TCR
diversity in the TIL/Tc was associated with improved survival in
all of these cancers (Fig. 3B–L) while clonality was not, although it
had borderline significance for OS in KIRC (Supplementary
Table 7).
Discussion
Our data shows that, as in melanoma, in various other cancers
TIL/Tc diversity is prognostic for OS in the absence of PD1
blockade, whereas pre-treatment TIL/Tc clonality is predictive of
response to anti-PD1 treatment. This is consistent with obser-
vations that on-treatment TIL/Tc clonality anticipates radi-
ological response to immunotherapy in melanoma8,16. Our
results suggest that high TCR diversity in TIL/Tc identifies
patients whose immune system achieves durable tumor control
without anti-PD1 therapy, whereas high TIL/Tc clonality iden-
tifies which patients will mount an effective anti-PD1-induced
immune response.
The reconstruction of the TCR using cancer transcriptomic
datasets is a powerful approach in defining the T cell repertoire in
solid tumors, but here we show that targeted TCR sequencing
approaches identify more unique TCR clonotypes than recon-
struction from RNA-Seq data and consequently targeted
sequencing could provide a more robust resolution when ana-
lyzing samples presenting limited numbers of TIL/Tc. Despite
this, we showed consistent results with the two platforms, sup-
porting our hypothesis that TIL/Tc repertoire analysis provides
new ways to explore delivery of personalized immunotherapy,
although we expect more sensitive and accurate approaches to
eventually replace existing state-of-the-art solutions.
With adjuvant PD1 CPB already approved in stage III mela-
noma and currently being trialed in stage II melanoma
(NCT03553836), the need for predictive and prognostic stratifi-
cation tools for CPB is becoming more pressing. This is parti-
cularly important for patients with intermediate-risk disease
where the odds of toxicity could outweigh the benefit of adjuvant
immunotherapy and where the TIL/Tc repertoire could provide a
much-needed reliable biomarker for patient selection.
More studies are needed to determine why high TIL/Tc clon-
ality is predictive of CPB benefit, whereas TIL/Tc diversity is
prognostic in the absence of CPB, but our findings nevertheless
have important clinical implications because of their potential to
contribute to the development of personalized therapeutic stra-
tegies through the identification of the patients who could better
benefit from treatments.
Methods
Patients. The training cohort patient samples do not involve clinical trials/clinical
trial-associated data, as patient samples were collected prior to standard-of-care
treatment. Biopsy pre-treatment samples from Manchester patients were pro-
spectively collected under the Manchester Cancer Research Centre (MCRC) Bio-
bank ethics application #18/NW/0092; the study was approved by MCRC Biobank
Access Committee application 13_RIMA_01. Biopsy pre-treatment samples and
clinical information from Padova patients were collected under the University of
Padova Department of Surgery, Oncology and Gastroenterology ethics application
04/03/2002 protocol #448 and Veneto Oncology Institute ethics approval 09/04/
2018 protocol #006264. Biopsy pre-treatment samples from Meldola patients were
collected under ethics application #5483/2018 of Comitato Etico della Romagna.
All patients gave written informed consent to the use of the samples for research
purposes. Clinical endpoints: date of death was obtained from clinical records (pre-
CPB training cohort), the original publications (pre-CPB validation cohorts), and
TCGA clinical information files. Radiological response information was obtained
from the original publications.
RNA sequencing. RNA was extracted from pre-treatment human fresh frozen
tumor samples using the AllPrep DNA/RNA Kit (Qiagen, Manchester, UK)
according to the manufacturer’s instructions: briefly, tissue samples were first lysed
and homogenized in a highly denaturing guanidineisothiocyanate-containing
buffer to inactivate DNases and RNases and ensure isolation of intact DNA and
RNA; the lysates were then passed through an AllPrep DNA membrane that, in
combination with the high-salt buffer, binded the genomic DNA that was then
eluted; ethanol was added to the flow-throughs from the AllPrep DNA membrane
to provide appropriate binding conditions for RNA, and the samples were then
applied to an RNeasy membrane; total RNA binded to the membranes and con-
taminants were washed away; high-quality RNA was then eluted in 45–70 μl water.
Indexed PolyA libraries were prepared using 200 ng of total RNA and 14 cycles of
amplification with the Agilent SureSelect Strand Specific RNA Library Prep Kit for
Illumina Sequencing (Agilent, G9691B, Santa Clara, CA, US). Libraries were
quantified by quantitative PCR (qPCR) using the KAPA Library Quantification Kit
for Illumina platforms (Kapa Biosystems Inc., KK4873, Wilmington, MA, US).
Paired-end 100 bp sequencing was carried out by clustering 15 pM of pooled
libraries on the cBot and sequenced on the Illumina HiSeq 2500 in high output
mode using TruSeq SBS V3 chemistry (Illumina Inc., San Diego, CA, US); average
of all samples was 68 million pass-filter (PF) reads (each end). The primers were all
supplied as part of the kits that are listed. After removing adapters using Cutadapt
(v1.14) and trimming poor quality base calls using Trimmomatic (v0.36)17, the
human reads were aligned to GRCh37 (release 75) using STAR (v2.5.1) aligner18.
Fig. 1 TIL/Tc TCR repertoire in melanoma biopsies is predictive for overall survival and response to PD1 CPB. A Survival curves for our metastatic
melanoma training cohort of patients treated with anti-PD1 drugs with high (green) or low (orange) pre-treatment TIL/Tc clonality (n= 16, cut-off= 0.06,
log-rank P= 0.0003), B predictive effect of TIL/Tc clonality on the relative hazard for death in the same cohort as A. Y-axis: log of relative hazard; a hazard
ratio (HR) of 1 corresponds to 0, upper values correspond to HR > 1, and lower values correspond to HR < 1. The blue curves represent the HR function and
“Rug plots” on curves show the density of the predictor (univariate Cox regression P= 0.0193); pointwise 95% confidence bands (shadowed area) are also
shown. C Survival curves for the metastatic melanoma validation cohort6, 7 of patients treated with anti-PD1 drugs with high (green) or low (orange) pre-
treatment TIL/Tc clonality (n= 106, cut-off= 0.10, log-rank P= 0.0039), D predictive effect of TIL/Tc clonality on the relative hazard of death in the same
cohort (univariate Cox regression P= 0.0225). E Violin plots of the pre-treatment TIL/Tc clonality distribution in patients who achieved radiological
response (green, n= 12, median= 0.23, SD= 0.09) and progressed (orange, n= 13, median= 0.14, SD= 0.07) to treatment with PD1 CPB in a metastatic
melanoma cohort9 (simple logistic regression log-likelihood ratio for association with probability of response= 8.6, P= 0.0033, n= 25) and F receiver
operating curve (ROC) of the linear regression response prediction (area under the curve= 0.89). G Violin plots of the pre-treatment TIL/Tc clonality
distribution in patients who achieved radiological response (green, n= 6, median= 0.15, SD= 0.09) and progressed (orange, n= 12, median= 0.04,
SD= 0.05) to treatment with PD1 CPB in a metastatic melanoma cohort8 (simple logistic regression log-likelihood ratio for association with probability of
response= 7.2, P= 0.007, n= 18) and H receiver operating curve (ROC) of the linear regression response prediction (area under the curve= 0.81).
I Violin plots of the pre-treatment TIL/Tc clonality distribution in patients who achieved radiological response (green, n= 9, median= 0.14, SD= 0.09)
and progressed (orange, n= 9, median= 0.06, SD= 0.05) to treatment with neoadjuvant PD1 CPB in an advanced melanoma cohort10 (simple logistic
regression log-likelihood ratio for association with probability of response= 4.5, P= 0.0340, n= 18) and J receiver operating curve (ROC) of the linear
regression response prediction (area under the curve= 0.74). Analyses are two-sided; TIL/Tc clonality and diversity are retained as continuous variables
in the regression analyses; n is single patient; single green dots represent single patients; horizontal dotted lines in the violin plots represent median and SD;
SD= standard deviation. Source data are provided as a Source data file.
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TCR analysis. CDR3 TCR sequence data generated by Bo Li et al.11 for the 29
TCGA cohorts were kindly made available by the authors; the clinical data for the
cohorts were downloaded from cBioportal in February 2018. CDR3 TCR sequences
were inferred from RNA Seq data from pre-treatment biopsies for the training
cohort samples using ImReP19; inclusion criterion for downstream analyses was
minimum four TCR sequences identified. Clonality was calculated with the func-
tion clonality from LymphoSeq R package; heatmaps were generated using Lym-
phoSeq, pheatmap, and ggplot2 R packages. The diversity was calculated using
Renyi index (α= 1) as per Spreafico et al.20.
Whole-exome sequencing snap-frozen tumor tissue was manually dissected by
sectioning (25-μm thick), and DNA was extracted from sections with an estimated
tumor cell percentage of at least 80% using the AllPrep DNA/RNA Kit (Qiagen)
according to the manufacturer’s instructions, as per description above. Germline
DNA was isolated from patients’ blood. DNA quantity was assessed using a Qubit®
2.0 Fluorometer (Life Technologies).
One microgram of genomic DNA was sheared using a Covaris S2 ultrasonicator
(Covaris, Inc.). Multiplexed libraries were prepared using the SureSelectXT Target
Enrichment System for Illumina Paired-End Sequencing and the SureSelect
Human All Exon V6 Capture Library (Agilent, G9641B/5190-8864).
Libraries were quantified by qPCR using the KAPA Library Quantification Kit
for Illumina platforms (Kapa Biosystems, Inc., KK4873). Paired-end 100 bp
sequencing was carried out by clustering 14 pM of pooled libraries on the cBot and
sequenced on the Illumina HiSeq 2500 in high output mode using TruSeq SBS V3
chemistry (Illumina, Inc.); average PF reads (each end) was 126 million for tumor
samples and 67 million for germline samples. The primers were all supplied as part
of the kits that are listed. After removing adapters using Cutadapt (v1.14) and
trimming poor quality base calls using Trimmomatic (v0.36), the reads were
aligned to the GRCh37 (release 75) human genome using BWA aligner (v0.7.7).
The PCR duplicate reads were filtered using Picard (v1.96), and the base quality
score recalibration and local INDEL realignments were performed using
GATKtools (v3.1). Using tumor–normal pairs, SNVs were identified using
MuTect21 (v1.1.7). Variant Effect Predictor (Ensembl version 73/84) was used to
annotate the mutations. Known variants present in dbSNP were excluded.
Mutational signature. Mutational signatures for TCGA SKCM cohort were
determined by fitting somatic SNVs with tri-nucleotide context to the 30 COSMIC
mutational signatures using deconstructSigs12 package using default parameters.
Signatures with contribution weights <6% were excluded.
PD-L1 quantification in pre-treatment biopsies. Pre-treatment biopsy samples
were fixed in 10% neutral buffered formalin (Sigma-Aldrich), processed, and
embedded in paraffin wax. Samples were sectioned (4 μm) and stained with
hematoxylin and eosin using standard protocols. Formalin-fixed paraffin-embed-
ded sections were deparaffinized using xylene and rehydrated passing through a
series of graded ethanol to distilled water steps. Heat-induced epitope retrieval
(125 °C, 60 s; 90 °C, 10 s) was performed using a Pascal pressure chamber (Dako)
with Dako target retrieval solution pH 6 (S203130, Agilent Technologies, Santa
Clara, California, US). Sections were then processed and stained with anti-PD-L1
22C3 PharmDx (Agilent Technologies, Santa Clara, CA, US) as per the
Fig. 2 TIL/Tc TCR repertoire in melanoma biopsies is prognostic for overall survival in absence of PD1 CPB. Analyses of TCGA skin melanoma cohort
(n= 412): A forest plot showing HR and 95% CI for significant covariates retained in the multivariate Cox regression prognostic model calculated using the
fast-backward method and the Akaike Information Criterion as a stopping rule (events= 147, model for OS global P < 0.001, concordance index= 0.71);
B survival curves for patients with high (blue) or low (pink) TIL/Tc diversity (cut-off= 3.49, log-rank P < 0.0001); C nomogram tailored on the final model
with the significant prognostic factors from A; the sum of the prognostic factor values corresponds to the survival probability at 24 and 60 months, an
example of the nomogram use is shown in Supplementary Fig. 6. Analyses are two-sided; TIL/Tc clonality and diversity are retained as continuous
variables in the regression analyses; n is single patient, OS is overall survival, HR is hazard ratio, CI is confidence interval; signature 7 is single base
substitution signature 7 version 212, 13. Source data are provided as a Source data file.
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manufacturer’s instructions: briefly, after peroxidase block for 5 min, the sections
were incubated with the 22C3 antibody using a concentration of 1:50 for 60 min at
room temperature and then incubated for 30 min at room temperature with the
linker antibody provided with the kit and specific to the host species of the primary
antibody; finally, the sections were incubated with a ready-to-use visualization
reagent provided with the kit and consisting of secondary antibody molecules and
horseradish peroxidase molecules coupled to a dextran polymer backbone. Sections
were then quantified by a clinical pathologist according to good clinical practice
guidelines for approved diagnostic PD-L1 quantification.
Statistics and reproducibility. All tests were two-sided and P values < 0.05 were
retained as significant. Unless otherwise specified, multivariate Cox regression was
used to calculate the hazard of death; fast-backward method was applied to select
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the covariates retained in the multivariate models (fastbw function in rms R
package, type= “individual”). The Akaike Information Criterion [AIC] as a stop-
ping rule was used to select the covariates in the final model in order to weight the
probability of both significance and prediction strength. The model performance
was quantified with C-indexes, calculated after validation with 200 bootstraps
(validate in rms R package, rule= “aic”) and compared with analysis of variance. A
nomogram (rms R package) was tailored on the final regression model for the
melanoma TCGA cohort; the total number of points derived by specifying the
covariate values was used to calculate the expected survival probabilities at 24 and
60 months; to proceed with the nomogram design, the missing values in the final
regression model were estimated with multiple imputations using additive
regression, bootstrapping, and predictive matching; a correction on the estimation
procedure was based on 200 multiple imputations. Cox–Snell residuals were used
to verify the proportional hazard hypothesis (with a P value >0.05 confirming the
hypothesis for all covariates retained in the multivariate models with the exception
of melanoma stage and breast cancer estrogen receptor status, which were time
dependent). Kaplan–Meier method with log-rank test was used to plot survival data
and patients’ allocation to groups were based on the biomarker cut-off determined
with OptimalCutpoints R package, with the exception that the TCR metrics were
retained as continuous variables for all the regression analyses to avoid cut-off
artifacts and selection bias. Simple logistic regression was applied to calculate the
log-likelihood ratio of radiological response to anti-PD1 therapy according to the
clonality of baseline biopsy TIL/Tc; the AUC of the ROC was calculated for the
parameters sensitivity and 1− specificity. We used the “rule of the thumb” to
determine the maximum number of covariates to use in the regression models22.
Samples with less than four TCR sequences were outbound for the algorithm to
calculate Renyi index and were excluded from the analysis. TCGA samples with
incomplete clinical annotation and no survival information were included in the
TCR analysis shown in Fig. 3A but were excluded from the survival and Cox
regression analyses in Fig. 2 and Fig. 3B–L. The investigators were blinded during
experiments; outcome assessment was performed after experiments. Analyses were
performed with GraphPad Prism version 7 (GraphPad Software, La Jolla, CA,
USA) or R (v. 3.6.3, The R Foundation for Statistical Computing, Vienna, Austria).
Data reporting follows REMARK guidelines (REporting recommendations for
tumor MARKer prognostic studies).
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
Sample metadata file are available as supplementary material. The RNA-Seq data for the
pre-treatment training cohort have been deposited in EGA under the accession code
EGAS00001005201. TCR sequencing data for the TCGA cohorts were kindly made
available by Bo Li et al.11. Treatment-naive melanoma biopsy TCR sequencing data of the
pre-treatment validation cohort reanalyzed here for OS were downloaded from https://
clients.adaptivebiotech.com/pub/weber-2018-cir (https://doi.org/10.21417/EY2019CIR)
and https://github.com/riazn/bms038_analysis. Pre-treatment melanoma biopsy TCR
sequencing data of the response analysis cohorts9,10,16 reanalyzed here were downloaded
from https://clients.adaptivebiotech.com/pub/tumeh-2014-nature, manuscript
supplementary material of the original manuscripts, and EGAS00001003178 EGA study
accession dataset EGAD00010001608 (only patients with matched baseline and week 3
tumor samples were included, to allow for AUC comparison of the ROC). The
progression-free survival data for the 11 patients in the neoadjuvant cohort who were
studied for progression-free survival (Supplementary Fig. 2a) were kindly made available
by the original manuscript authors. In-del data for TCGA clear cell renal carcinoma
cohort were kindly made available by Turajlic et al.14. Source data are provided with
this paper.
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n= 597; THYM thymoma, n= 93). Source data are provided as a Source data file.
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